Sézary syndrome

October 10, 2018October 10, 2018

9 in 10 Heavily Treated CTCL Patients See Benefits with IPH4102, Phase 1 Trial Shows

News

IPH4102, Innate Pharma’s investigational antibody, reduced tumor volume in 36% of patients with cutaneous T-cell lymphoma (CTCL) in a Phase 1 trial. Patients were heavily pre-treated, having received at least two ... Read more

August 17, 2018August 17, 2018

FDA-Approved Poteligeo for Two Types of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration’s (FDA) recent approval of Poteligeo (mogamulizumab-kpkc) was based on a Phase 3 trial that showed Poteligeo significantly slowed disease progression in adults with relapsed or ... Read more

August 9, 2018

Poteligeo Approved in US for Treating 2 Cutaneous T-cell Lymphoma Subtypes

News

Poteligeo (mogamulizumab-kpkc) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides and Sézary syndrome — two types of cutaneous T-cell lymphoma — in patients ... Read more

November 29, 2017November 29, 2017

FDA to Review Mogamulizumab as Treatment for Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will review the use of mogamulizumab as a treatment for cutaneous T-cell lymphoma (CTCL) in patients who received at least one prior line of ... Read more

October 12, 2017

Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants

News

A Phase 2 trial is currently enrolling participants to evaluate 4SC‘s investigational therapy resminostat as a maintenance therapy for advanced-stage cutaneous T-cell lymphoma (CTCL). The RESMAIN study (NCT02953301) is being conducted at about ... Read more

August 28, 2017August 28, 2017

FDA Grants Breakthrough Therapy Status to Lymphoma Treatment Poteligeo

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to Poteligeo (mogamulizumab) as a treatment for mycosis fungoides and sézary syndrome, the most common subtypes of cutaneous T-cell lymphoma, ... Read more

July 28, 2016July 28, 2016

Cutaneous T-Cell Lymphoma May Respond Longer to Different Romidepsin Dose Regimen

News

Patients with cutaneous T-cell lymphoma (CTCL) who are treated with romidepsin may have longer response periods with every other week dosing, or even once per month dosing, than with the standard dosing ... Read more

March 3, 2016March 3, 2016

Cutaneous T-cell Lymphoma Phase 1 Clinical Trial of MiR-155 Inhibitor Now Enrolling Patients

News

miRagen Therapeutics, Inc., announced that it has started a Phase 1 clinical trial (NCT02580552) of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155. The trial’s primary ... Read more

November 11, 2015November 11, 2015

Sézary Syndrome Patients’ Genome IDs Mutations that Might Lead to Treatments

News

Genomic profiling analysis of Sézary syndrome patients has revealed key mutations in genes essential to T-cell signaling and cell cycle regulation. The research paper from The Baylor College of Medicine ... Read more